Evidence map›Paper›PMID 38214660›Full record

ArticlemAbs

Engineering hydrophobicity and manufacturability for optimized biparatopic antibody-drug conjugates targeting c-MET.

Andreas Evers, Simon Krah, Deniz Demir, Ramona Gaa, Desislava Elter, Christian Schroeter, Stefan Zielonka, Nicolas Rasche, Julia Dotterweich, Christine Knuehl and 1 more

Open access · goldAbstract read
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Andreas EversAntibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Simon KrahAntibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Deniz DemirAntibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Ramona GaaAntibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Desislava ElterAntibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Christian SchroeterADC and Targeted Therapeutics, Merck Healthcare KGaA, Darmstadt, Germany.
Stefan ZielonkaAntibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Nicolas RascheADC and Targeted Therapeutics, Merck Healthcare KGaA, Darmstadt, Germany.
Julia DotterweichResearch Unit Oncology, Merck Healthcare KGaA, Darmstadt, Germany.
Christine KnuehlResearch Unit Oncology, Merck Healthcare KGaA, Darmstadt, Germany.
Achim DoernerAntibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.ORCID 0000-0002-4741-8039
Merck (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optimal combinations of paratopes assembled into a biparatopic antibody have the capacity to mediate high-grade target cross-linking on cell membranes, leading to degradation of the target, as well as antibody and payload delivery in the case of an antibody-drug conjugate (ADC). In the work presented here, molecular docking suggested a suitable paratope combination targeting c-MET, but hydrophobic patches in essential binding regions of one moiety necessitated engineering. In addition to rational design of HCDR2 and HCDR3 mutations, site-specific spiking libraries were generated and screened in yeast and mammalian surface display approaches. Comparative analyses revealed similar positions amendable for hydrophobicity reduction, with a broad combinatorial diversity obtained from library outputs. Optimized variants showed high stability, strongly reduced hydrophobicity, retained affinities supporting the desired functionality and enhanced producibility. The resulting biparatopic anti-c-MET ADCs were comparably active on c-MET expressing tumor cell lines as REGN5093 exatecan DAR6 ADC. Structural molecular modeling of paratope combinations for preferential inter-target binding combined with protein engineering for manufacturability yielded deep insights into the capabilities of rational and library approaches. The methodologies of

Indexed as

Antineoplastic AgentsImmunoconjugatesAnimalsCell Line, TumorHydrophobic and Hydrophilic InteractionsMammalsMolecular Docking SimulationAntineoplastic AgentsImmunoconjugatesAntibody engineeringBiparatopic ADCc-METhydrophobicitymanufacturability

Identifiers

PMID38214660
PMCPMC10793681
OpenAlexW4390793519

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.